1. Volume 22, Issue 1, Pages 132-139 (January 2014)
Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma 
Whay-Kuang Chia, Marissa Teo, Who-Whong Wang, Bernett Lee, Soo-Fan Ang, Wai-Meng Tai, Chit-Lai Chee, Joanna Ng, Rebecca Kan, Wan-Teck Lim, Sze-Huey Tan, Whee-Sze Ong, Yin-Bun Cheung, Eng-Huat Tan, John E Connolly, Stephen Gottschalk, Han-Chong Toh 
Molecular Therapy 
Volume 22, Issue 1, Pages (January 2014)
DOI: /mt
Copyright © 2013 The American Society of Gene & Cell Therapy Terms and Conditions

2. Figure 1
Scheme of clinical trial. For details see text. CTLs, cytotoxic T lymphocytes; EBV, Epstein–Barr virus; LCL, lymphoblastoid cell line; PBMC, peripheral blood mononuclear cell.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2013 The American Society of Gene & Cell Therapy Terms and Conditions

3. Figure 2
Survival outcomes for patients on study. (a) Overall survival (OS). (b) Progression free survival.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2013 The American Society of Gene & Cell Therapy Terms and Conditions

4. Figure 3
Presence of LMP2-specific T cells in cytotoxic T lymphocyte (CTL) product correlates with outcome. Patients (n = 25) receiving CTL products that contained LMP2-specific T cells had a significantly improved overall survival compared with those (n = 9) who received CTL product lacking LMP2 specificity (hazard ratio: 0.29; 95% CI: 0.12–0.74; P = 0.006). One patient was excluded from the analysis because we could not determine the LMP2 status of the infused CTL line.
Molecular Therapy  , DOI: ( /mt )
Copyright © 2013 The American Society of Gene & Cell Therapy Terms and Conditions